These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 6893992

  • 1. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization.
    Costa T, Marie PJ, Scriver CR, Cole DE, Reade TM, Nogrady B, Glorieux FH, Delvin EE.
    J Clin Endocrinol Metab; 1981 Mar; 52(3):463-72. PubMed ID: 6893992
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK, Lyles KW, Haussler MR, Harrelson JM.
    J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
    [Abstract] [Full Text] [Related]

  • 3. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets.
    Glorieux FH, Marie PJ, Pettifor JM, Delvin EE.
    N Engl J Med; 1980 Oct 30; 303(18):1023-31. PubMed ID: 6252463
    [Abstract] [Full Text] [Related]

  • 4. Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3.
    Scriver CR, Reade T, Halal F, Costa T, Cole DE.
    Arch Dis Child; 1981 Mar 30; 56(3):203-7. PubMed ID: 7212758
    [Abstract] [Full Text] [Related]

  • 5. Successful treatment of genetically hypophosphatemic mice by 1 alpha-hydroxyvitamin D3 but not 1,25-dihydroxyvitamin D3.
    Beamer WG, Wilson MC, DeLuca HF.
    Endocrinology; 1980 Jun 30; 106(6):1949-55. PubMed ID: 6892799
    [Abstract] [Full Text] [Related]

  • 6. Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse.
    Marie PJ, Travers R, Glorieux FH.
    Calcif Tissue Int; 1982 Mar 30; 34(2):158-64. PubMed ID: 6282410
    [Abstract] [Full Text] [Related]

  • 7. Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets.
    Chesney RW, Mazess RB, Rose P, Hamstra AJ, DeLuca HF, Breed AL.
    Pediatrics; 1983 Apr 30; 71(4):559-67. PubMed ID: 6300745
    [Abstract] [Full Text] [Related]

  • 8. Effect of 1,25-dihydroxyvitamin D3 on phosphate homeostasis in the X-linked hypophosphatemic (Hyp) mouse.
    Tenenhouse HS, Scriver CR.
    Endocrinology; 1981 Aug 30; 109(2):658-60. PubMed ID: 6894727
    [Abstract] [Full Text] [Related]

  • 9. X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy.
    Petersen DJ, Boniface AM, Schranck FW, Rupich RC, Whyte MP.
    J Bone Miner Res; 1992 Jun 30; 7(6):583-97. PubMed ID: 1414477
    [Abstract] [Full Text] [Related]

  • 10. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets.
    Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K.
    J Clin Endocrinol Metab; 1992 Sep 30; 75(3):879-85. PubMed ID: 1517380
    [Abstract] [Full Text] [Related]

  • 11. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N, Catto GR, Edward N, Fraser RA, O'Riordan JL, Papapoulos SE, Adami S.
    Proc Eur Dial Transplant Assoc; 1980 Sep 30; 17():543-7. PubMed ID: 6972529
    [Abstract] [Full Text] [Related]

  • 12. Supranormal 25-hydroxyvitamin D and subnormal 1,25-dihydroxyvitamin D: their role in X-linked hypophosphatemic rickets.
    Chesney RW, Mazess RB, Rose P, Hamstra AJ, DeLuca HF.
    Am J Dis Child; 1980 Feb 30; 134(2):140-3. PubMed ID: 6243443
    [Abstract] [Full Text] [Related]

  • 13. Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice.
    Ecarot B, Glorieux FH, Desbarats M, Travers R, Labelle L.
    J Bone Miner Res; 1995 Mar 30; 10(3):424-31. PubMed ID: 7785464
    [Abstract] [Full Text] [Related]

  • 14. Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3.
    Gundberg CM, Cole DE, Lian JB, Reade TM, Gallop PM.
    J Clin Endocrinol Metab; 1983 May 30; 56(5):1063-7. PubMed ID: 6601111
    [Abstract] [Full Text] [Related]

  • 15. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG, Goldstein DA, Malluche HH.
    Kidney Int; 1980 Oct 30; 18(4):409-18. PubMed ID: 7014981
    [No Abstract] [Full Text] [Related]

  • 16. Vitamin D metabolites and bone mineralization in man.
    Bordier P, Rasmussen H, Marie P, Miravet L, Gueris J, Ryckwaert A.
    J Clin Endocrinol Metab; 1978 Feb 30; 46(2):284-94. PubMed ID: 750606
    [Abstract] [Full Text] [Related]

  • 17. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL, Felsenfeld AJ, Llach F.
    Arch Intern Med; 1983 Jun 30; 143(6):1205-11. PubMed ID: 6344827
    [Abstract] [Full Text] [Related]

  • 18. Vitamin D dependency: replacement therapy with calcitriol?
    Delvin EE, Glorieux FH, Marie PJ, Pettifor JM.
    J Pediatr; 1981 Jul 30; 99(1):26-34. PubMed ID: 6265615
    [Abstract] [Full Text] [Related]

  • 19. Healing of bone lesions with 1,25-dihydroxyvitamin D3 in the young X-linked hypophosphatemic male mouse.
    Marie PJ, Travers R, Glorieux FH.
    Endocrinology; 1982 Sep 30; 111(3):904-11. PubMed ID: 6896684
    [Abstract] [Full Text] [Related]

  • 20. The effect of 1,25-dihydroxycholecalciferol on renal tubular reabsorption of phosphate, intestinal absorption of calcium and bone histology in hypophosphataemic renal tubular rickets.
    Russell RG, Smith R, Preston C, Walton RJ, Woods CG, Henderson RG, Norman AW.
    Clin Sci Mol Med; 1975 Mar 30; 48(3):177-86. PubMed ID: 163719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.